Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement

Glenis K. Scadding*, Peter W. Hellings, Claus Bachert, Leif Bjermer, Zuzana Diamant, Philippe Gevaert, Anette Kjeldsen, Jorge Kleine-Tebbe, Ludger Klimek, Antonella Muraro, Graham Roberts, Andreas Steinsvik, Martin Wagenmann, Ulrich Wahn

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    26 Citations (Scopus)
    78 Downloads (Pure)


    Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea, and coughing.

    This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on AIT.

    Original languageEnglish
    Article number100124
    Number of pages4
    JournalThe World Allergy Organization journal
    Issue number5
    Publication statusPublished - May-2020


    • Allergy
    • Rhinitis
    • Asthma
    • Treatment
    • Control
    • COVID-19
    • Symptoms
    • Smell and taste
    • Allergen-specific immunotherapy

    Cite this